Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

5.930 +0.060 (+1.02%)

Streaming Delayed Price Updated: 1:06 PM EST, Nov 13, 2025 Add to My Watchlist

Price and Volume

Volume	750,679
Open	5.830
Bid (Size)	5.920 (200)
Ask (Size)	5.940 (100)
Prev. Close	5.870
Today's Range	5.730 - 6.035
52wk Range	5.430 - 20.75
Shares Outstanding	45,711,975
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗

November 10, 2025

Via Stocktwits

Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗

November 10, 2025

Via Stocktwits

Performance

YTD	-60.4%	-60.4%
1 Month	-11.8%	-11.8%
3 Month	-28.6%	-28.6%
6 Month	-22.7%	-22.7%
1 Year	-67.2%	-67.2%

More News

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Preview: Capricor Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗

September 25, 2025

Via Stocktwits

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗

November 04, 2025

Via Stocktwits

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Why Capricor Therapeutics Stock Is Surging Today ↗

September 25, 2025

Via Benzinga

Gapping stocks in Thursday's session ↗

September 25, 2025

Via Chartmill

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

September 16, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

September 15, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Via NewMediaWire

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Via TheNewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

September 14, 2025

From Pomerantz LLP

Via GlobeNewswire

CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit

September 14, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR

September 12, 2025

Via NewMediaWire

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR

September 12, 2025

Via TheNewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

September 12, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR

September 11, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR

September 11, 2025

Via NewMediaWire

Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR

September 11, 2025

Via TheNewswire.com

CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit

September 11, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

September 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) - September 15, 2025 Deadline to Join - Contact Levi & Korsinsky

September 10, 2025

Via NewMediaWire

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?

Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?

Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?

The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market

What is the current price of Capricor Therapeutics, Inc. - Common Stock?

The current price of Capricor Therapeutics, Inc. - Common Stock is 5.930

When was Capricor Therapeutics, Inc. - Common Stock last traded?

The last trade of Capricor Therapeutics, Inc. - Common Stock was at 11/13/25 01:06 PM ET

What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?

The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 271.07M

How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?

Capricor Therapeutics, Inc. - Common Stock has 271M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.